Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Oxford Gene Technology (OGT) has launched its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel for the detection of ultra-low frequency measurable residual disease (MRD)–associated ...
To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results